Yuhan Corporation’s Lazertinib’s Promising Clinical Trial Results Boost U.S. Market Prospects
Yuhan Corporation’s key product Lazertinib (domestic brand name Leclaza) has shown promising data in clinical trials. Yuhan Corporation has recently
Read More